浏览全部资源
扫码关注微信
1.杨浦区中医医院肿瘤科(上海 200090)
2.上海中医药大学附属龙华医院肿瘤二科(上海 200032)
Received:10 January 2024,
Published:10 April 2025
移动端阅览
高红芳,周兰,周己扬,等.基于ATF2⁃Nrf2通路探讨肺岩宁调控非小细胞肺癌铁死亡敏感性的作用机制[J].上海中医药杂志,2025,59(4):64-71.
GAO Hongfang,ZHOU Lan,ZHOU Jiyang,et al.Regulation of Feiyanning on sensitivity of non‑small cell lung cancer to ferroptosis based on ATF2‑Nrf2 pathway[J].Shanghai Journal of Traditional Chinese Medicine,2025,59(4):64-71.
高红芳,周兰,周己扬,等.基于ATF2⁃Nrf2通路探讨肺岩宁调控非小细胞肺癌铁死亡敏感性的作用机制[J].上海中医药杂志,2025,59(4):64-71. DOI: 10.16305/j.1007-1334.2025.2401037.
GAO Hongfang,ZHOU Lan,ZHOU Jiyang,et al.Regulation of Feiyanning on sensitivity of non‑small cell lung cancer to ferroptosis based on ATF2‑Nrf2 pathway[J].Shanghai Journal of Traditional Chinese Medicine,2025,59(4):64-71. DOI: 10.16305/j.1007-1334.2025.2401037.
目的
2
探讨肺岩宁对非小细胞肺癌铁死亡敏感性的影响及其机制。
方法
2
利用肺岩宁干预铁死亡诱导剂埃拉斯汀(Erastin)诱导的非小细胞肺癌A549细胞铁死亡,通过细胞计数试剂盒(CCK-8)检测细胞活性改变,通过谷胱甘肽(GSH)检测试剂盒、亚铁离子(Fe
2+
)检测试剂盒、丙二醛(MDA)检测试剂盒分别检测细胞内GSH水平、Fe
2+
水平及MDA水平改变。通过高内涵成像检测活性氧(ROS)敏感荧光探针标记的细胞内氧化应激改变。通过Western blot法检测激活转录因子2(ATF2)、核因子2相关因子2(Nrf2)、溶质载体家族7成员11(SLC7A11)及谷胱甘肽过氧化物酶4(GPX4)表达情况。
结果
2
与对照组比较,低浓度肺岩宁对A549细胞存活率影响差异无统计学意义(
P
>
0.05),而中浓度肺岩宁(
P
<
0.01)及高浓度肺岩宁(
P
<
0.001)可明显降低A549细胞存活率。与各浓度Erastin组比较,肺岩宁联合各浓度Erastin组均可明显降低A549细胞存活率,差异有统计学意义(
P
<
0.05,
P
<
0.01)。与肺岩宁组、Erastin组、Erastin联合肺岩宁组比较,铁死亡抑制剂铁抑素-1(Ferrostatin-1)干预后各组细胞存活率均明显提高,差异有统计学意义(
P
<
0.05,
P
<
0.01,
P
<
0.001)。Western blot检测显示,与对照组比较,Erastin能明显上调A549细胞内ATF2表达(
P
<
0.05),下调Nrf2(
P
<
0.001)、SLC7A11(
P
<
0.05)及GPX4表达(
P
<
0.01)。与对照组比较,肺岩宁可显著下调ATF2(
P
<
0.05)及Nrf2表达(
P
<
0.01)
,而对SLC7A11及GPX4表达无显著影响(
P
>
0.05)。此外,与对照组比较,Erastin联合肺岩宁可显著下调ATF2(
P
<
0.05)、Nrf2(
P
<
0.001)、SLC7A11(
P
<
0.001)及GPX4表达(
P
<
0.001)。而与Erastin组比较,Erastin联合肺岩宁可显著下调ATF2(
P
<
0.001)、Nrf2(
P
<
0.05)、SLC7A11(
P
<
0.05)及GPX4表达(
P
<
0.05)。
结论
2
肺岩宁可以增强非小细胞肺癌细胞对铁死亡诱导剂的敏感性,其机制可能与其调控的ATF2-Nrf2通路有关。
Objective
2
To explore the effect of Feiyanning (FYN) on sensitivity of non-small cell lung cancer (NSCLC) to ferroptosis and its mechanism.
Methods
2
Erastin-induced NSCLC A549 cells were treated with FYN. Cell viability was examined using cell counting kit-8 (CCK-8) assay. Intracellular level of reduced glutathione (GSH), Fe
2+
and malondialdehyde (MDA) were examined using GSH assay kit, ferrous ion content assay kit and MDA assay kit, respectively. Intracellular reactive oxygen species (ROS) was labeled using ROS-sensitive probe and determined through high-content imaging system. The expressions of activating transcription factor 2 (ATF2), nuclear factor E2-related factor 2 (Nrf2), solute carrier family 7 member 11(SLC7A11) and glutathione peroxidase 4 (GPX4) were examined using Western blot.
Results
2
Although low concentration of FYN showed no significant effect on the cell viability of A549 cells, medium and high concentration of FYN significantly decreased the cell viability of A549 cells (
P
<
0.01,
P
<
0.001) compared with that of the control group. Compared with each concentration group of Erastin, FYN combined with each concentration of Erastin significantly reduced the cell viability of A549 cells, and the difference was statistically significant (
P
<
0.05,
P
<
0.01). Compared with FYN group, Erastin group
, and Erastin combined with FYN group, the cell viability in each group was significantly improved after the intervention of Ferrostatin-1 (
P
<
0.05,
P
<
0.01,
P
<
0.001). Western blot analysis showed that compared with the control group, Erastin could significantly up-regulate ATF2 expression (
P
<
0.05), down-regulate the expressions of Nrf2 (
P
<
0.001), SLC7A11 (
P
<
0.05) and GPX4 (
P
<
0.01) in A549 cells. Compared with the control group, FYN significantly down-regulated the expressions of ATF2 (
P
<
0.05) and Nrf2 (
P
<
0.01), but had no significant effect on SLC7A11 and GPX4 expressions (
P
>
0.05). In addition, compared with the control group, Erastin combined with FYN significantly down-regulated the expressions of ATF2 (
P
<
0.05), Nrf2 (
P
<
0.001), SLC7A11 (
P
<
0.001) and GPX4 (
P
<
0.001). Compared with Erastin group, Erastin combined with FYN significantly down-regulated the expressions of ATF2 (
P
<
0.001), Nrf2 (
P
<
0.05), SLC7A11 (
P
<
0.05) and GPX4 (
P
<
0.05).
Conclusion
2
FYN can enhance the sensitivity of NSCLC to ferroptosis inducer, which might be through its regulation on ATF2-Nrf2 pathway.
SIEGEL R L , MILLER K D , WAGLE N S , et al . Cancer statistics, 2023 [J]. CA Cancer J Clin , 2023 , 73 ( 1 ): 17 - 48 .
XIA C , DONG X , LI H , et al . Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J]. Chin Med J (Engl) , 2022 , 135 ( 5 ): 584 - 590 .
CHEN P , LIU Y , WEN Y , et al . Non-small cell lung cancer in China [J]. Cancer Commun (Lond) , 2022 , 42 ( 10 ): 937 - 970 .
MILLER M , HANNA N . Advances in systemic therapy for non-small cell lung cancer [J]. BMJ , 2021 , 375 : n2363 .
CHAFT J E , RIMNER A , WEDER W , et al . Evolution of systemic therapy for stages Ⅰ-Ⅲ non-metastatic non-small cell lung cancer [J]. Nat Rev Clin Oncol , 2021 , 18 ( 9 ): 547 - 557 .
BAILEY H , LEE A , ECCLES L , et al . Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey [J]. BMC Cancer , 2023 , 23 ( 1 ): 603 .
郑展 , 徐振晔 , 陆琪俊 , 等 . 肺岩宁颗粒治疗男性精气两亏型中晚期肺鳞癌的临床研究 [J]. 上海中医药杂志 , 2022 , 56 ( 6 ): 42 - 45 .
刘畅 , 赵晓珍 , 王中奇 , 等 . 肺岩宁方联合抗瘤增效方对中晚期肺腺癌患者化疗后癌因性疲乏、免疫功能及肿瘤标志物影响的临床研究 [J]. 上海中医药杂志 , 2019 , 53 ( 6 ): 49 - 53 .
TANG D , CHEN X , KANG R , et al . Ferroptosis: molecular mechanisms and health implications [J]. Cell Res , 2021 , 31 ( 2 ): 107 - 125 .
REN Z , HU M , WANG Z , et al . Ferroptosis-related genes in lung adenocarcinoma: prognostic signature and immune, drug resistance, mutation analysis [J]. Front Genet , 2021 , 12 : 672904 .
ZHU L M , SHI H X , SUGIMOTO M , et al . Feiyanning Formula induces apoptosis of lung adenocarcinoma cells by activating the mitochondrial pathway [J]. Front Oncol , 2021 , 11 : 690878 .
马玥 , 王立芳 , 郑展 , 等 . 肺岩宁方联合顺铂对肺癌A549细胞生物学行为的影响 [J]. 中华中医药杂志 , 2022 , 37 ( 6 ): 3452 - 3456 .
方旭鹏 , 方丹 , 邓海滨 , 等 . 肺岩宁方联合吉非替尼对肺腺癌H1975细胞体外增殖的影响 [J]. 上海中医药杂志 , 2022 , 56 ( 8 ): 79 - 83 .
WANG L , FU H , SONG L , et al . Overcoming AZD9291 resistance and metastasis of NSCLC via ferroptosis and multitarget interference by nanocatalytic sensitizer plus AHP-DRI-12 [J]. Small , 2023 , 19 ( 4 ): e2204133 .
白月琴 , 吴中华 , 刘畅 , 等 . 肺岩宁联合吉非替尼对人非小细胞肺癌H1975细胞生物学行为的影响 [J]. 中华中医药杂志 , 2018 , 33 ( 11 ): 5204 - 5207 .
LI Y , YAN H , XU X , et al . Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway [J]. Oncol Lett , 2022 , 19 ( 1 ): 323 - 333 .
YU M , GAI C , LI Z , et al . Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells [J]. Cancer Sci , 2019 , 110 ( 10 ): 3173 - 3182 .
PAN X , LIN Z , JIANG D , et al . Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis [J]. Oncol Lett , 2019 , 17 ( 3 ): 3001 - 3008 .
NI J , CHEN K , ZHANG J , et al . Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells [J]. Biochem Biophys Res Commun , 2021 , 567 : 154 - 160 .
URSINI F , MAIORINO M . Lipid peroxidation and ferroptosis: The role of GSH and GPX4 [J]. Free Radic Biol Med , 2020 , 152 : 175 - 185 .
ZILKA O , SHAH R , LI B , et al . On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death [J]. ACS Cent Sci , 2017 , 3 ( 3 ): 232 - 243 .
KSHETRIMAYUM V , HEISNAM R , KEITHELLAKPAM O S , et al . Paris polyphylla Sm. induces reactive oxygen species and caspase 3‑mediated apoptosis in colorectal cancer cells in vitro and potentiates the therapeutic significance of fluorouracil and cisplatin [J]. Plants(Basel) , 2023 , 12 ( 7 ): 1446 .
ZHENG Q , WANG X , GAO T , et al . Exploring the pharmacological and molecular mechanisms of Salvia chinensis Benth in colorectal cancer: a network pharmacology and molecular docking study [J]. Medicine (Baltimore) , 2023 , 102 ( 50 ): e36602 .
YU J , JI H , DONG X , et al . Apoptosis of human gastric carcinoma MGC-803 cells induced by a novel Astragalus membranaceus polysaccharide via intrinsic mitochondrial pathways [J]. Int J Biol Macromol , 2019 , 126 : 811 - 819 .
ZHOU R , CHEN H , CHEN J , et al . Extract from Astragalus membranaceus inhibits breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway [J]. BMC Complement Altern Med , 2018 , 18 ( 1 ): 83 .
LIU X , LI Z , LI M , et al . Icariside Ⅱ overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF [J]. Oncol Rep , 2020 , 44 ( 1 ): 360 - 370 .
CHOI N R , CHOI W , ZHU A , et al . Exploring the therapeutic effects of Atractylodes macrocephala Koidz against human gastric cancer [J]. Nutrients , 2024 , 16 ( 7 ): 965 .
JONES S , JANARDHANAN K K . Antioxidant and antitumor activity of Ganoderma lucidum (Curt.: Fr.) P. Karst.—Reishi (Aphyllophoromycetideae) from South India [J]. Int J Med Mushrooms , 2000 , 2 ( 3 ): 249 - 257 .
王菊勇 , 郭净 , 董昌盛 , 等 . 肺岩宁方在人肺癌细胞系对肿瘤坏死因子α诱导的iNOS和COX-2表达的影响 [J]. 中西医结合学报 , 2012 , 10 ( 6 ): 695 - 700 .
HE F , RU X , WEN T . NRF2, a transcription factor for stress response and beyond [J]. Int J Mol Sci , 2020 , 21 ( 13 ): 4777 .
DODSON M , CASTRO-PORTUGUEZ R , ZHANG D D . NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis [J]. Redox Biol , 2019 , 23 : 101107 .
SHIN D , KIM E H , LEE J , et al . Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer [J]. Free Radic Biol Med , 2018 , 129 : 454 - 462 .
FENG L , ZHAO K , SUN L , et al . SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis [J]. J Transl Med , 2021 , 19 ( 1 ): 367 .
HAN K , JIN X , GUO X , et al . Nrf2 knockout altered brain iron deposition and mitigated age-related motor dysfunction in aging mice [J]. Free Radic Biol Med , 2021 , 162 : 592 - 602 .
LIU N , LIN X , HUANG C . Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance [J]. Br J Cancer , 2020 , 122 ( 2 ): 279 - 292 .
KIM J W , KIM M J , HAN T H , et al . FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner [J]. Cell Death Dis , 2023 , 14 ( 8 ): 567 .
WATSON G , RONAI Z A , LAU E . ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease [J]. Pharmacol Res , 2017 , 119 : 347 - 357 .
YANG H , HUEBNER K , HAMPEL C , et al . ATF2 loss promotes 5‑FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway [J]. BMC Cancer , 2023 , 23 ( 1 ): 480 .
GIANNOUDIS A , MALKI M I , RUDRARAJU B , et al . Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer [J]. Breast Cancer Res , 2020 , 22 ( 1 ): 126 .
LO IACONO M , MONICA V , VAVALÀ T , et al . ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway [J]. Int J Cancer , 2015 , 136 ( 11 ): 2598 - 2609 .
TANG F , XU Y , GAO E , et al . Amentoflavone attenuates cell proliferation and induces ferroptosis in human gastric cancer by miR-496/ATF2 axis [J]. Chem Biol Drug Des , 2023 , 102 ( 4 ): 782 - 792 .
XU X , LI Y , WU Y , et al . Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer [J]. Redox Biol , 2023 , 59 : 102564 .
WANG C , LI P , PENG Y , et al . Integrative RNA-Seq and ATAC-Seq analysis reveals the migration-associated genes involved in antitumor effects of herbal medicine Feiyanning on lung cancer cells [J]. Front Genet , 2021 , 12 : 799099 .
WANG L , CHEN Y , MI Y , et al . ATF2 inhibits anti-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis [J]. Biochem Biophys Res Commun , 2021 , 558 : 216 - 223 .
0
Views
0
下载量
0
CSCD
0
CNKI被引量
Publicity Resources
Related Articles
Related Author
Related Institution